Bedaquiline resistance-associated genetic mutations and minimum inhibitory concentrations in drug-resistant tuberculosis clinical isolates from Limpopo province, South Africa
Frontiers in Microbiology · 21.05.2026 · 17
DOI: 10.3389/fmicb.2026.1803115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 21.05.2026. Verfasst von Pleasure Malope und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Microbiology, Department of Pathology, Faculty of Health Sciences, University of Limpopo, Mankweng, South Africa. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Bedaquiline (BDQ) resistance is a significant threat to tuberculosis (TB) control efforts, particularly in areas with a high burden of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, such as South Africa. Determining the minimum inhibitory concentration (MIC) of BDQ and identifying the associated resistance-conferring mutations are critical for understanding resistance patterns and guiding therapeutic decisions. This study investigated BDQ resistance in Mycobacterium tuberculosis isolates across five districts in Limpopo, South Africa, by analyzing the relationship between minimum inhibitory concentrations (MICs) and resistance-conferring mutations.
Method
This study is a cross-sectional study including 147 drug-resistant (DR-TB) isolates obtained from the Polokwane laboratory, Limpopo province, South Africa. The study used phenotypic MIC drug susceptibility testing and whole-genome sequencing (WGS) to investigate BDQ susceptibility patterns. MIC determination and genetic analysis were performed on all isolates with an MIC of >1 μg/mL and a subset of those with an MIC of <1 μg/mL as a control for sequencing.
Results
Of the 147 DR-TB isolates included, 128 (87.1%) had an MIC of ≤1 μg/mL (susceptible), while 19 (12.9%) had an MIC of >1 μg/mL (resistant). Whole-genome sequencing revealed that mutations in Rv0678 (89.1%), including frameshift and codon substitution variants, were mainly associated with drug resistance, while mutations in the atpE (5.1%) and Rv1979c (5.1%) were also identified. Of the BDQ-R strains, the Euro-American (L4) lineage was dominant, accounting for 62.5%.
Conclusion
In this study, BDQ resistance was primarily driven by Rv0678 mutations. As BDQ is one of the few potent drugs available for treating DR-TB, there is a critical need for early detection and continuous surveillance to prevent the spread of resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Microbiology, Department of Pathology, Faculty of Health Sciences, University of Limpopo, Mankweng, South Africa.
- Centre for Tuberculosis, National Institute of Communicable Diseases, Johannesburg, South Africa.
- Department of Medical Microbiology, National Health Laboratory Services, Polokwane, South Africa.
Zitieren
APA
Malope, P., Lekalakala-Mokaba, M. R., Ngcamu, D. C., Said, H., Rukasha, I., & Omar, S. V. (2026). Bedaquiline resistance-associated genetic mutations and minimum inhibitory concentrations in drug-resistant tuberculosis clinical isolates from Limpopo province, South Africa. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1803115
Vancouver
Malope P, Lekalakala-Mokaba MR, Ngcamu DC, Said H, Rukasha I, Omar SV. Bedaquiline resistance-associated genetic mutations and minimum inhibitory concentrations in drug-resistant tuberculosis clinical isolates from Limpopo province, South Africa. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1803115
BibTeX
@article{Malope2026,
author = {Malope, Pleasure and Lekalakala-Mokaba, Molebogeng Ruth and Ngcamu, Dumisani Cyril and Said, Halima and Rukasha, Ivy and Omar, Shaheed Vally},
title = {Bedaquiline resistance-associated genetic mutations and minimum inhibitory concentrations in drug-resistant tuberculosis clinical isolates from Limpopo province, South Africa},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1803115}
}
EUVIMED